Aerie Pharmaceuticals (NASDAQ:AERI) Issues Earnings Results, Beats Estimates By $0.20 EPS

Aerie Pharmaceuticals (NASDAQ:AERIGet Rating) released its earnings results on Thursday. The company reported ($0.32) earnings per share (EPS) for the quarter, topping analysts’ consensus estimates of ($0.52) by $0.20, Fidelity Earnings reports. During the same quarter in the previous year, the company posted ($0.67) earnings per share.

Aerie Pharmaceuticals Trading Up 20.9 %

NASDAQ:AERI opened at $8.91 on Friday. Aerie Pharmaceuticals has a 1 year low of $4.81 and a 1 year high of $17.21. The firm’s fifty day simple moving average is $7.16 and its 200 day simple moving average is $7.44.

Institutional Inflows and Outflows

Hedge funds and other institutional investors have recently bought and sold shares of the company. US Bancorp DE grew its position in Aerie Pharmaceuticals by 174.4% in the 1st quarter. US Bancorp DE now owns 3,685 shares of the company’s stock worth $34,000 after purchasing an additional 2,342 shares during the last quarter. Advisor Group Holdings Inc. grew its position in Aerie Pharmaceuticals by 33.9% in the 1st quarter. Advisor Group Holdings Inc. now owns 6,863 shares of the company’s stock worth $62,000 after purchasing an additional 1,739 shares during the last quarter. BNP Paribas Arbitrage SA grew its position in Aerie Pharmaceuticals by 34.8% in the 1st quarter. BNP Paribas Arbitrage SA now owns 12,123 shares of the company’s stock worth $110,000 after purchasing an additional 3,131 shares during the last quarter. Hsbc Holdings PLC acquired a new stake in Aerie Pharmaceuticals in the 1st quarter worth $159,000. Finally, First Republic Investment Management Inc. grew its position in Aerie Pharmaceuticals by 9.3% in the 1st quarter. First Republic Investment Management Inc. now owns 20,443 shares of the company’s stock worth $186,000 after purchasing an additional 1,743 shares during the last quarter.

Analyst Upgrades and Downgrades

Separately, StockNews.com upgraded shares of Aerie Pharmaceuticals from a “hold” rating to a “buy” rating in a research report on Tuesday, June 28th.

Aerie Pharmaceuticals Company Profile

(Get Rating)

Aerie Pharmaceuticals, Inc, a pharmaceutical company, focuses on the discovery, development, and commercialization of ophthalmic therapies for open-angle glaucoma, dry eye, diabetic macular edema, and wet age-related macular degeneration in the United States. Its products include Rhopressa, a once-daily eye drop to reduce elevated intraocular pressure (IOP) in patients with open-angle glaucoma or ocular hypertension; and Rocklatan, a once-daily fixed-dose combination of Rhopressa and latanopros to reduce IOP to treat patients with open-angle glaucoma or ocular hypertension.

Further Reading

Earnings History for Aerie Pharmaceuticals (NASDAQ:AERI)

Receive News & Ratings for Aerie Pharmaceuticals Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Aerie Pharmaceuticals and related companies with MarketBeat.com's FREE daily email newsletter.